Atherosclerosis Market
Atherosclerosis Market Forecasts to 2034 - Global Analysis By Disease Type (Coronary Artery Atherosclerosis, Carotid Artery Atherosclerosis, Peripheral Artery Atherosclerosis, Renal Artery Atherosclerosis and Aortic Atherosclerosis), Diagnosis Modality, Treatment Modality, Route of Administration, Distribution Channel, End User and By Geography
Market Dynamics:
Driver:
Increasing prevalence of cardiovascular diseases and associated metabolic disorders
The increasing prevalence of cardiovascular diseases and metabolic disorders is a major driver of the atherosclerosis market. Rising rates of diabetes, obesity, hypertension, and elevated cholesterol contribute to the development and progression of arterial plaque formation. Aging populations and sedentary lifestyles are further increasing cardiovascular risk across many regions. Greater awareness of preventive healthcare, expanding cholesterol screening programs, and improved access to cardiovascular diagnostics are encouraging earlier disease detection. Additionally, growing adoption of lipid-lowering medications and minimally invasive vascular interventions is supporting treatment demand and long-term market expansion.
Restraint:
High treatment costs and limited access to advanced cardiovascular diagnostics
High treatment costs and unequal access to advanced cardiovascular services are significant restraints on market growth. Diagnostic procedures such as computed tomography angiography, magnetic resonance angiography, and intravascular imaging can involve substantial equipment and operational expenses. Advanced lipid-lowering therapies, endovascular interventions, and surgical procedures may also impose considerable financial burdens on patients and healthcare systems. Limited reimbursement coverage and inadequate specialist availability in developing regions can restrict treatment adoption. Additionally, complex treatment regimens, medication-related adverse effects, and poor patient adherence may reduce the effectiveness of long-term disease management.
Opportunity:
Development of innovative lipid-lowering therapies and precision cardiovascular medicine
Advancements in lipid-lowering therapies and precision cardiovascular medicine are creating significant opportunities for market participants. Pharmaceutical companies are developing treatments targeting PCSK9, lipoprotein(a), and other pathways associated with atherosclerotic cardiovascular disease. RNA-based therapies, gene-editing approaches, and novel cholesterol-lowering medications may expand treatment options for patients with persistent cardiovascular risk. Improvements in vascular imaging, artificial intelligence-assisted diagnostics, and personalized risk assessment are supporting earlier intervention. Growing investment in cardiovascular research and expanding access to preventive treatment programs may further accelerate market development.
Threat:
Regulatory complexities and increasing competition from generic cardiovascular medications
Stringent regulatory requirements and growing competition from generic medications present significant threats to the atherosclerosis market. Developers of innovative cardiovascular therapies must demonstrate clinical safety, effectiveness, and meaningful cardiovascular outcomes through extensive clinical studies. Patent expirations and the widespread availability of low-cost generic statins can create pricing pressure for branded pharmaceutical manufacturers. Potential adverse effects, treatment discontinuation, and uncertainty surrounding reimbursement policies may also influence market adoption. Additionally, healthcare budget constraints, supply chain disruptions, and variations in clinical guidelines can create challenges for pharmaceutical and medical technology companies.
Covid-19 Impact:
The COVID-19 pandemic affected the atherosclerosis market through disruptions in routine cardiovascular screening, diagnostic imaging, and elective vascular procedures. Healthcare systems prioritized emergency services, resulting in delayed consultations and interventions for some patients with chronic cardiovascular conditions. Interruptions in preventive care and lipid monitoring complicated long-term risk management. However, telemedicine consultations, remote patient monitoring, and electronic prescription services gained importance during the pandemic. Subsequent recovery in cardiovascular healthcare services, renewed emphasis on preventive medicine, and continued adoption of digital health technologies supported market stabilization and further development.
The coronary artery atherosclerosis segment is expected to be the largest during the forecast period
The coronary artery atherosclerosis segment is expected to account for the largest market share during the forecast period due to the substantial burden of coronary artery disease and its associated treatment requirements. Plaque accumulation within coronary arteries can reduce myocardial blood supply and increase the risk of angina and acute coronary events. Management frequently involves lipid-lowering medications, antiplatelet therapies, diagnostic imaging, and revascularization procedures when clinically indicated. Increasing cardiovascular screening, improved diagnostic capabilities, and expanding availability of minimally invasive coronary interventions are supporting segment development. Continued investment in cardiovascular therapeutics further strengthens its market position.
The endovascular procedures segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the endovascular procedures segment is predicted to witness the highest growth rate due to increasing adoption of minimally invasive techniques for managing selected atherosclerotic vascular conditions. Angioplasty, stent placement, and other catheter-based interventions can restore blood flow in appropriately selected patients while reducing procedural invasiveness compared with certain open surgical approaches. Advancements in drug-eluting stents, vascular imaging, and catheter technologies are improving procedural capabilities. Growing availability of specialized cardiovascular centers and increasing demand for shorter hospital stays are supporting adoption. Continued technological innovation may further accelerate segment growth.
Region with largest share:
During the forecast period, North America is expected to hold the largest market share, supported by advanced cardiovascular healthcare infrastructure, substantial healthcare expenditure, and widespread availability of diagnostic and therapeutic technologies. The United States represents a major market due to the significant burden of atherosclerotic cardiovascular disease, established specialist treatment networks, and strong pharmaceutical research activity. Increasing adoption of advanced lipid-lowering medications, vascular imaging, and minimally invasive interventions is supporting market development. Continued investment in preventive cardiovascular care and innovative treatment technologies further strengthens regional performance.
Region with highest CAGR:
Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR due to increasing cardiovascular disease prevalence, rapidly aging populations, and expanding healthcare infrastructure. China, India, Japan, South Korea, and Australia represent important markets for atherosclerosis diagnosis and treatment. Rising incidence of diabetes, hypertension, and dyslipidemia is increasing demand for preventive cardiovascular services. Growing healthcare expenditure, improving access to diagnostic imaging, and expanding adoption of advanced cardiovascular therapies are supporting regional development. Government initiatives promoting early screening and increasing investment in specialized cardiac facilities may further encourage market growth.
Key players in the market
Some of the key players in the Atherosclerosis Market include AstraZeneca, Bayer AG, Merck & Co. Inc., Novartis AG, Sanofi, Pfizer Inc., Amgen, Regeneron Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, AbbVie Inc., Boehringer Ingelheim, Daiichi Sankyo Company, Limited, Novo Nordisk A/S, Ionis Pharmaceuticals, Verve Therapeutics, Inc., and NewAmsterdam Pharma.
Key Developments:
In September 2026, Ionis Pharmaceuticals announced that its partner Novartis had reported topline Phase III results from the Lp(a)HORIZON study evaluating pelacarsen in patients with elevated lipoprotein(a) and established cardiovascular disease. The development represents an important milestone in investigating RNA-targeted approaches to cardiovascular risk reduction.
In August 2026, NewAmsterdam Pharma reported a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending marketing authorization for obicetrapib and its fixed-dose combination with ezetimibe. The investigational treatments target elevated LDL cholesterol in patients requiring additional lipid management.
In July 2026, Amgen announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion supporting broader use of Repatha (evolocumab) in adults with established or high risk for atherosclerotic cardiovascular disease. The recommendation was supported by Phase III VESALIUS-CV trial findings demonstrating cardiovascular event reduction in high-risk patients.
Disease Types Covered:
• Coronary Artery Atherosclerosis
• Carotid Artery Atherosclerosis
• Peripheral Artery Atherosclerosis
• Renal Artery Atherosclerosis
• Aortic Atherosclerosis
Diagnosis Modalities Covered:
• Laboratory Testing
• Ultrasound Imaging
• Computed Tomography Angiography (CTA)
• Magnetic Resonance Angiography (MRA)
• Catheter-Based Angiography
• Intravascular Imaging
Treatment Modalities Covered:
• Pharmacological Therapy
• Endovascular Procedures
• Surgical Procedures
Routes of Administration Covered:
• Oral
• Parenteral
Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
End Users Covered:
• Hospitals
• Specialty Cardiovascular Centers
• Specialty Clinics
• Ambulatory Surgical Centers
Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
§ Saudi Arabia
§ United Arab Emirates
§ Qatar
§ Israel
§ Rest of Middle East
o Africa
§ South Africa
§ Egypt
§ Morocco
§ Rest of Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 Research Framework
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 Market Dynamics and Trend Analysis
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 Competitive and Strategic Assessment
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 Global Atherosclerosis Market, By Disease Type
5.1 Coronary Artery Atherosclerosis
5.2 Carotid Artery Atherosclerosis
5.3 Peripheral Artery Atherosclerosis
5.4 Renal Artery Atherosclerosis
5.5 Aortic Atherosclerosis
6 Global Atherosclerosis Market, By Diagnosis Modality
6.1 Laboratory Testing
6.2 Ultrasound Imaging
6.3 Computed Tomography Angiography (CTA)
6.4 Magnetic Resonance Angiography (MRA)
6.5 Catheter-Based Angiography
6.6 Intravascular Imaging
7 Global Atherosclerosis Market, By Treatment Modality
7.1 Pharmacological Therapy
7.2 Endovascular Procedures
7.3 Surgical Procedures
8 Global Atherosclerosis Market, By Route of Administration
8.1 Oral
8.2 Parenteral
9 Global Atherosclerosis Market, By Distribution Channel
9.1 Hospital Pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacies
10 Global Atherosclerosis Market, By End User
10.1 Hospitals
10.2 Specialty Cardiovascular Centers
10.3 Specialty Clinics
10.4 Ambulatory Surgical Centers
11 Global Atherosclerosis Market, By Geography
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 Strategic Market Intelligence
12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment
13 Industry Developments and Strategic Initiatives
13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives
14 Company Profiles
14.1 AstraZeneca
14.2 Bayer AG
14.3 Merck & Co. Inc.
14.4 Novartis AG
14.5 Sanofi
14.6 Pfizer Inc.
14.7 Amgen
14.8 Regeneron Pharmaceuticals
14.9 Eli Lilly and Company
14.10 GlaxoSmithKline
14.11 Johnson & Johnson
14.12 AbbVie Inc.
14.13 Boehringer Ingelheim
14.14 Daiichi Sankyo Company, Limited
14.15 Novo Nordisk A/S
14.16 Ionis Pharmaceuticals
14.17 Verve Therapeutics, Inc.
14.18 NewAmsterdam Pharma
List of Tables
1 Global Atherosclerosis Market Outlook, By Region (2023-2034) ($MN)
2 Global Atherosclerosis Market Outlook, By Disease Type (2023-2034) ($MN)
3 Global Atherosclerosis Market Outlook, By Coronary Artery Atherosclerosis (2023-2034) ($MN)
4 Global Atherosclerosis Market Outlook, By Carotid Artery Atherosclerosis (2023-2034) ($MN)
5 Global Atherosclerosis Market Outlook, By Peripheral Artery Atherosclerosis (2023-2034) ($MN)
6 Global Atherosclerosis Market Outlook, By Renal Artery Atherosclerosis (2023-2034) ($MN)
7 Global Atherosclerosis Market Outlook, By Aortic Atherosclerosis (2023-2034) ($MN)
8 Global Atherosclerosis Market Outlook, By Diagnosis Modality (2023-2034) ($MN)
9 Global Atherosclerosis Market Outlook, By Laboratory Testing (2023-2034) ($MN)
10 Global Atherosclerosis Market Outlook, By Ultrasound Imaging (2023-2034) ($MN)
11 Global Atherosclerosis Market Outlook, By Computed Tomography Angiography (CTA) (2023-2034) ($MN)
12 Global Atherosclerosis Market Outlook, By Magnetic Resonance Angiography (MRA) (2023-2034) ($MN)
13 Global Atherosclerosis Market Outlook, By Catheter-Based Angiography (2023-2034) ($MN)
14 Global Atherosclerosis Market Outlook, By Intravascular Imaging (2023-2034) ($MN)
15 Global Atherosclerosis Market Outlook, By Treatment Modality (2023-2034) ($MN)
16 Global Atherosclerosis Market Outlook, By Pharmacological Therapy (2023-2034) ($MN)
17 Global Atherosclerosis Market Outlook, By Endovascular Procedures (2023-2034) ($MN)
18 Global Atherosclerosis Market Outlook, By Surgical Procedures (2023-2034) ($MN)
19 Global Atherosclerosis Market Outlook, By Route of Administration (2023-2034) ($MN)
20 Global Atherosclerosis Market Outlook, By Oral (2023-2034) ($MN)
21 Global Atherosclerosis Market Outlook, By Parenteral (2023-2034) ($MN)
22 Global Atherosclerosis Market Outlook, By Distribution Channel (2023-2034) ($MN)
23 Global Atherosclerosis Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
24 Global Atherosclerosis Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
25 Global Atherosclerosis Market Outlook, By Online Pharmacies (2023-2034) ($MN)
26 Global Atherosclerosis Market Outlook, By End User (2023-2034) ($MN)
27 Global Atherosclerosis Market Outlook, By Hospitals (2023-2034) ($MN)
28 Global Atherosclerosis Market Outlook, By Specialty Cardiovascular Centers (2023-2034) ($MN)
29 Global Atherosclerosis Market Outlook, By Specialty Clinics (2023-2034) ($MN)
30 Global Atherosclerosis Market Outlook, By Ambulatory Surgical Centers (2023-2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY

We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.